Core Viewpoint - Runmed-B (02297) experienced a significant decline of 10.0% in stock price, trading at 0.45 HKD per share as of 14:25 on August 20, with a transaction volume of 17.5763 million HKD [1] Company Overview - Runmed Medical Co., Ltd. aims to become a global leader in vascular interventional surgical robots, with key products including the caFFR system, caIMR system, and FlashBot vascular interventional surgical robot [1] - The company has established a global R&D, production, sales, and service network, collaborating with top medical centers and implementing a strict quality inspection system [1] - Runmed has successfully obtained certification for its medical device quality management system [1] Financial Performance - As of the 2024 annual report, Runmed-B reported total operating revenue of 39.824 million HKD and a net loss of 113 million HKD [2]
润迈德-B(02297)下跌10.0%，报0.45元/股